Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Legacy Financial Advisors Inc.

Legacy Financial Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.1% during the fourth quarter, Holdings Channel reports. The fund owned 749 shares of the biopharmaceutical company’s stock after acquiring an additional 81 shares during the quarter. Legacy Financial Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $658,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REGN. FMR LLC grew its position in shares of Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock valued at $8,098,661,000 after purchasing an additional 669,517 shares during the period. Northern Trust Corp grew its holdings in Regeneron Pharmaceuticals by 3.3% in the 3rd quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after buying an additional 34,326 shares during the period. Morgan Stanley increased its stake in shares of Regeneron Pharmaceuticals by 2.7% during the 3rd quarter. Morgan Stanley now owns 970,957 shares of the biopharmaceutical company’s stock valued at $799,061,000 after acquiring an additional 25,792 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. American Century Companies Inc. now owns 916,718 shares of the biopharmaceutical company’s stock worth $754,422,000 after acquiring an additional 30,050 shares during the period. Finally, International Assets Investment Management LLC grew its holdings in Regeneron Pharmaceuticals by 76,169.5% in the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock valued at $519,148,000 after purchasing an additional 590,314 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded up $19.39 during mid-day trading on Friday, reaching $957.00. The company’s stock had a trading volume of 547,373 shares, compared to its average volume of 509,442. The company has a current ratio of 6.40, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $684.80 and a twelve month high of $998.33. The business has a 50 day moving average price of $943.75 and a 200-day moving average price of $896.33. The firm has a market cap of $105.04 billion, a price-to-earnings ratio of 28.27, a PEG ratio of 2.69 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the previous year, the business posted $10.96 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on REGN. Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday. UBS Group raised their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $977.77.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $950.00, for a total value of $950,000.00. Following the sale, the executive vice president now directly owns 38,543 shares of the company’s stock, valued at $36,615,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Joseph J. Larosa sold 1,000 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $950.00, for a total value of $950,000.00. Following the sale, the executive vice president now owns 38,543 shares of the company’s stock, valued at approximately $36,615,850. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 10,095 shares of company stock worth $9,664,476 in the last 90 days. 8.83% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.